OBJECTIVE： To observe therapeutic efficacy and safety of rosuvastatin combined with ezetimibe in the treatment of acute myocardial infarction （AMI） of coronary heart disease patients. METHODS： 84 coronary heart disease patients with AMI were randomly divided into treatment group and control group with 42 cases in each group. Control group were treated with Ezetimibe tablets 10 mg， qd. Treatment group were additionally treated with Rosuvastatin tablets 10-40 mg， qd， on the basis of control group. Both groups received 4 weeks of treatment. Clinical efficacy was observed in 2 groups， and the changes of LVEF， LVEDV， myohemoglobin， CRP， MPO and Hcy were also observed before and after treatment. The occurrence of ADR was recorded during treatment. RESULTS： The total effective rate of treatment group （90.48％） was significantly higher than that of control group （71.43％）， with statistical significance （P＜0.05）； after treatment， LVEF level in both groups were obviously increased， and the treatment group was higher than the control group； LVEDV level， myohemoglobin， CRP， MPO and Hcy in both groups were obvious decreased in 2 groups after treatment， and the treatment group was lower than the control group，with statistical significance （P＜0.05）. No serious ADR was found in 2 groups during treatment. CONCLUSIONS： The clinical efficacy of rosuvastatin combined with ezetimibe in the treatment of AMI of coronary heart disease patients， can improve LVEF， LVEDV， myohemoglobin， CRP， MPO and Hcy levels significantly， with good safety.